Bristol-Myers Squibb Company (BMY) will begin trading ex-dividend on September 30, 2021. Returns Potential A 15% price target upside from sell-side analysts. All comparisons are made versus the same period in 2021 unless otherwise stated. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of Turning Point Therapeutics free of charge at tptherapeutics.com. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the timing of the tender offer and the subsequent merger, (ii) the number of shares of the Turning Point Therapeutics common stock that will be tendered in the tender offer, (iii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iv) the risk that legal proceedings may be instituted related to the merger agreement, (v) any competing offers or acquisition proposals for Turning Point Therapeutics, (vi) the possibility that various conditions to the consummation of the tender offer or the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the offer or the acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction. Recently declared a week off fro everybody between xmas and new years. The case is UMB Bank NA v Bristol-Myers Squibb (NYSE: BMY) Co et al, U.S. District Court, Southern District of New York, No. Available to US-based employeesChange location, Comparable to many others in the same league. Holiday Calendar; Earnings Calendar; A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. Our expansive library of resources covers a wide range of special interest topics in multiple languages through a variety of top learning and development resources powered by LinkedIn Learning. Bristol-Myers Squibb, one of the world's largest pharmaceutical companies, arose out of a 1989 merger and today focuses on the manufacture of prescription medicines for the treatment of cancer . Best place for vacation and time off, BMS incentivize family time. 2020; 2022 Calendar Settings. The actual financial impact of this transaction may differ from the expected financial impact described in this communication. TOKYO & NEW YORK, Jun 17, 2021--(BUSINESS WIRE)--Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). U.S. revenues increased 11% to $7.5 billion in the quarter. Elizabeth Mily joined Bristol Myers Squibb Co. as executive vice president of strategy and business development in March 2020 after 27 years in investment banking. So we are always workingpushing the boundaries of what's possible to transform lives today and tomorrow. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. Jun 11, 2021 5:45PM EDT. Written by Zacks Equity Research for Zacks ->. Use of Non-GAAP Financial Information and Financial Guidance, In discussing financial guidance, Bristol Myers Squibb refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Agenus saw its stock skyrocket on Tuesday after the company announced a $1.6 billion deal with Bristol-Myers Squibb (NYSE: BMY), a $146 billion giant, to develop Agenus promising new cancer antibody treatment. Your response will be removed from the review this cannot be undone. In November, the company announced that the Phase 3 CheckMate -816 trial met the co-primary endpoint of improved event-free survival (EFS) in patients with resectable Stage IB to IIIA non-small cell lung cancer. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com., Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. BMS Benefits and Work Life. Yield Attractiveness B 3.27% forward dividend yield. Normal for industry. As detailed in my profile, I have over 10 years of experience in the pharmaceutical industry (GSK Vaccines, UCB Pharma, Bristol-Myers Squibb). A cash dividend payment of $0.49 per share is scheduled to be paid on August 02, 2021. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer. At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file a tender offer statement on Schedule TO and Turning Point Therapeutics will file a recommendation statement on Schedule 14D-9. 0000013014 00000 n
Add to Google Calendar. 0000008852 00000 n
We have the responsibility to protect and respect personal information. Amortization of acquired intangible assets decreased 4% to $2.4 billion in the quarter primarily due to an extended marketed product rights exclusivity period. 867 0 obj We regularly promote awareness of this resource to employees. Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, Standards of Business Conduct and Ethics. ** Included as part of the new product portfolio
0000030151 00000 n
We claim: 1. <>stream
0000115702 00000 n
(( g 2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio. Bristol ups aid. Stress management, well-being, and integrating work with life all determine the energy we bring each day to our work, family and community. <>z{^)P"PPq@ 6/ 0000004547 00000 n
This culture of inclusion encourages everyone to pursue innovative ideas, develop leadership capabilities and gain valuable, diverse experiences to shape exciting careers. Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article . Add to Microsoft Outlook. INVESTORS AND TURNING POINT THERAPEUTICS STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED TENDER OFFER DOCUMENTS) AND THE RELATED SOLICITATION/ RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 THAT WILL BE FILED BY TURNING POINT THERAPEUTICS WITH THE SEC, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE CONSIDERED BY TURNING POINT THERAPEUTICSS INVESTORS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Bristol Myers Squibb expects repotrectinib to be approved in the U.S. in the second half of 2023 and become a new standard of care for patients with ROS1-positive NSCLC in the first-line setting. Bristol Myers Squibb will not tolerate practices that violate the intent of our Mission and Commitment. (EPS) for full-year 2021 between $3.18 and $3.38, up from its previous forecast of a range of $3.12 to $3.32. . With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile., Todays news builds upon our long legacy of pioneering next-generation medicines for patients with cancer, said Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb. Your future colleagues at Bristol Myers Squibb are impacting lives every day. Goldman Sachs & Co. LLC is serving as the exclusive financial advisor to Turning Point Therapeutics, and Cooley LLP is serving as legal counsel. Learn more! Investor Relations: investor.relations@bms.com, Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021, https://www.businesswire.com/news/home/20220204005037/en/, Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%, driven by. 1 Bristol Myers Squibb Reports First Quarter Financial Results for 2022 Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY; or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96; Includes Net Impact of ($0.10) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 There's been plenty of good news for Bristol Myers Squibb (BMY 0.13%) . 0000192949 00000 n
For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. When you join one of our diverse, high-achieving teams, youll collaborate each day to help transform the lives of patients around the world. Gross margin is expected to be approximately 78% for GAAP and for non-GAAP. Diaspora holiday schedule. 0000005488 00000 n
A cash dividend payment of $0.49 per share is scheduled to be paid on November 01, 2021. Meet Our Team in Tampa, FL Meet Our Team in Tampa, FL Possibility Lives at BMS Find out why possibility lives at Bristol Myers Squibb Asha on Skills 2 Give Volunteer Program Asha on Skills 2 Give Volunteer Program Selling, General & Admin. "Simply because we are attracting the best talent to better serve patients now, while at the same time we're focusing on developing strategic partnerships to grow our pipeline of next generation assets and deliver on our commitment to the patients of tomorrow.". Add to Apple Calendar. <>/Filter/FlateDecode/Index[87 726]/Length 47/Size 813/Type/XRef/W[1 1 1]>>stream
We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Events and Presentations. "Simply because we are attracting the best talent to better serve patients now, while at the same time we're focusing on developing strategic partnerships to grow our pipeline of next generation assets and deliver on our commitment to the patients of tomorrow." Senior Research Investigator salaries ($93k), Research Investigator II salaries ($108k), Associate Research Scientist I salaries ($70k), Senior Research Investigator II salaries ($132k), Associate Research Scientist II salaries ($77k). Our Insights for Success program is offered to diverse employees to enhance their organizational and personal career success and ensure equitable leadership throughout the company. squibb bristolmyers bristol myers pharma pharmaceutical culture balance more Ok but hard to move within the company Analyst (Former Employee) - Tampa - February 4, 2023 Indeed Featured review Always evolving due to the industry. 0000042941 00000 n
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Bristol-Myers Squibb's shares . Compliance with data privacy laws on a global basis is an essential business practice for Bristol Myers Squibb. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication. Year. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. 07/29/21 : Interim 2021 Earnings Release (Projected) 10/28/21 : Q3 2021 Earnings Release (Projected) 01/27/22 : FY 2021 Earnings Release (Projected) 04/28/22 Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. Jun 13, 2021 9:01AM EDT. In addition, the financial guidance provided in this release relies on assumptions about the duration and severity of the COVID-19 pandemic, timing of the return to a more stable business environment, patient and physician behaviors, buying patterns and clinical trial activities, which may prove to be incorrect. Learn about our safety approach to COVID-19 > At Bristol Myers Squibb, the work you do-often in support of emerging therapeutic areas that require new methods of thinking and working-will help people prevail over serious diseases. Materials on this website may contain information about the Companys future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Moving to the bottom line, Bristol Myers Squibb grew its non-GAAP EPS by 22.7% YOY to $2.00 in the third quarter. We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. 0000042754 00000 n
The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this communication that are calculated and presented in accordance with GAAP and are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company's baseline performance, supplement or enhance management, analysts and investors overall understanding of the companys underlying financial performance and trends and facilitate comparisons among current, past and future periods. Bristol Myers Squibb will not tolerate practices that violate the intent of our Mission and Commitment. (, In December, the company announced that its Board of Directors approved an increase in the quarterly dividend and authorized an additional $15 billion, multi-year share repurchase program. Youll find valuable developmental opportunities to help connect you to your passion and drive your career forward. Monday Jan 11, 2021 07:30 AM ET. Our mission to enhance the lives of patients requires an investment in a strong learning culture. No forward-looking statement can be guaranteed. Aug 2010 - Present12 years 8 months. In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). This led to the automatic termination of the CVR agreement Jan. 1,2021 rendering the CVRs as ineligible for payment under the agreement. Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.. A REMS program was included in the initial application for mavacamten. The extension will allow sufficient time to review information pertaining to updates of the proposed Risk Evaluation Mitigation Strategy (REMS). Mar 02, 2023 (Prime PR Wire via Comtex) -- This "Organ Transplant Rejection Medication Market" study analyses the market and offers thorough insights to help. Bristol-Myers confirmed that it had signed a deal to develop Agenus antibody treatment known as AGEN1777. Materials related to the call will be available at the same website prior to the conference call. Required to work every rotating weekends, some holidays, and during adverse weather conditions in support of . The tender offer described in this communication has not yet commenced. Headquarters Location 430 E. 29th Street 14th Floor New York, New York, 10016, United States Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; challenges inherent in new product development, including obtaining and maintaining regulatory approval; the companys ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to the companys and the companys suppliers manufacturing sites; the impact of integrating the companys and Celgenes business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the companys suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on the companys competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on the companys information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in the companys information systems and networks; the companys ability to execute its financial, strategic and operational plans; the companys ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; the companys dependency on several key products; any decline in the companys future royalty streams; the companys ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; the companys ability to attract and retain key personnel; the impact of the companys significant additional indebtedness that it incurred in connection with the Celgene acquisition and the MyoKardia acquisition; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the impact of adverse outcomes in lawsuits, claims, proceedings and government investigations; the impact of our exclusive forum provision in our by-laws for certain lawsuits on our stockholders ability to obtain a judicial forum that it finds favorable for such lawsuits; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on the companys operations. Key 2022 GAAP and non-GAAP line-item guidance assumptions are: The 2022 financial guidance excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. With support and coaching from your colleagues, youre encouraged to take on stretch assignments that maximize your learning experience. The same period a year ago included license and acquisition charges related to Dragonfly, an in-process research and development (IPR&D) impairment charge and cash settlement of MyoKardia unvested stock awards. 0000005073 00000 n
July 28 (Reuters) - Bristol Myers Squibb Co (BMY.N) reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. The 2022 Country 2 Country 4 Cancer ride organised by Bristol Myers Squibb will feature more than 90 of the company's employees cycling in seven European countries from 2-19th September in support of the Union for International Cancer Control (UICC) and selected members to raise funds with the aim of accelerating the fight against cancer and Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. THIS LICENSE AGREEMENT (this "Agreement") dated as of March 30, 1998 by and between Bristol-Myers Squibb Company, a corporation duly organized and existing under the laws of the State of Delaware, having offices at P.O. 0000003506 00000 n
Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. Operating expenses, consisting of marketing, selling and administrative expenses and research and development expenses, are expected to decrease by approximately 10% for GAAP and be in-line with 2021 levels for non-GAAP. 813 0 obj I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib. In November, the company announced that the U.S. Food and Drug Administration (FDA) has extended the review of the New Drug Application (NDA) for mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy to April 28, 2022. With your consent, we may also use third party cookies to analyze your usage of the website. Returns Risk A+ 0.4 beta (5Y monthly). Income tax benefit was approximately $510 million despite pre-tax earnings of $1.9 billion in the quarter primarily due to the impact of internal transfers of certain intangible assets of $1.0 billion. 0000042527 00000 n
Bristol-Myers Squibb expanded its collaboration to help The Max Foundation reach 45% The biopharmaceutical company reported $1.74 earnings per share for the quarter, missing analysts' consensus estimates of $1.82 by ($0.08). This website uses cookies to provide website functionality. You may read any reports, statements or other information filed by the company or Turning Point Therapeutics with the SEC at no charge on the SECs website at www.sec.gov. ET on April 29, 2021 Bristol-Myers Squibb (NYSE:BMY) SVP Adam Dubow sold 3,119 shares of the business's stock in a transaction dated Wednesday, May 5th. Breakout Session - Bristol Myers Squibb Presents: The Future of Cancer Care: Transformative Innovation for All . Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference, which will be webcast on Tuesday, May 11, 2021. Bristol-Myers Squibb has a 1 year low of $54.07 and a 1 year high of $67.16. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. Play. "The first of the new aircraft will enter service in late-2023, with the bulk to . Ensure day-day logistics operations are meet. We routinely post important information for investors on our website, BMS.com, in the Investors section. BMY: Get the latest Bristol-Myers Squibb stock price and detailed information including BMY news, historical charts and realtime prices. Bristol Myers Squibb posted third quarter revenues of $11.2 billion, a decrease of 3%, driven by recent LOE products (primarily Revlimid) and foreign exchange impacts, partially offset by in-line products (primarily Eliquis and Opdivo) and our new product portfolio . Turning Point Therapeutics Board of Directors unanimously recommends that Turning Point Therapeutics shareholders tender their shares in the tender offer. Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. When adjusted for foreign exchange impact, international revenues increased 7%. . Apr 27, 2021 (The Expresswire) -- Covid -19 Impact to global Stroke Treatment Drugs Market for 2015-2025. 0000009073 00000 n
A method of treating a disorder mediated by BRD9 comprising administering an effective amount of a compound of Formula: or a pharmaceutically acceptable salt thereof 866 0 obj A dds details on agreement, background. The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82.